Radiotherapy combinations

Chair: Maria Hawkins, CRUK MRC Oxford Institute for Radiation Oncology, UK
Speaker: Kaye Williams, The University of Manchester, UK
Speaker: Susan Short, University of Leeds, UK
Speaker: Alan Melcher, The Institute of Cancer Research, UK


Room: Carron

There is an unmet need for rational approaches to drugradiotherapy combinations on the basis of our molecular understanding of radiobiology. There are several agents in development and testing that target different biological effects of radiation (DNA damage repair inhibitors, metabolic inhibitors, IGF signal transduction, immune modulators). Understanding tumour specific effects and how normal tissues are react are both key for preclinical and clinical work. The paradigm shift that radiation has more than a cytotoxic effect and causes immunogenic cell death of cancer cells, modulates antigen presentation by cancer cells, and alters the microenvironment within the irradiated field has gained traction in the last years. Understanding how, when and which combination would benefit specific tumour situations is still under evaluation. An area of increasing importance will be the development of suitable biomarkers that will be able to reliably assess the effect on target, immune effector stimulation for example. Such profile of biomarkers will aid in searching for an optimal combination of radiotherapy and novel agents and will allow patient selection and response prediction.